{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:28:37Z","timestamp":1790710117421,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"NSERC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000082","name":"Cystic Fibrosis Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000082","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jcf.2021.05.006","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T07:10:40Z","timestamp":1621840240000},"page":"881-890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["VIP reduction in the pancreas of F508del homozygous CF mice and early signs of Cystic Fibrosis Related Diabetes (CFRD)"],"prefix":"10.1016","volume":"20","author":[{"given":"Anna","family":"Semaniakou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Chappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younes","family":"Anini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Chappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2021.05.006_bib0001","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1432-1033.1972.tb01903.x","article-title":"Isolation from porcine-intestinal wall of a Vasoactive Octacosapeptide related to secretin and to glucagon","volume":"28","author":"Said","year":"1972","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.jcf.2021.05.006_bib0002","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.169.3951.1217","article-title":"Polypeptide with broad biological activity: isolation from small intestine","volume":"169","author":"Said","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.jcf.2021.05.006_bib0003","unstructured":"Said SI. Vasoactive Intestinal Polypeptide (VIP) in lung function and disease 1991. Nihon Kyobu Shikkan Gakkai Zasshi. 1991;29(12):1525-31. PMID: 1687288."},{"key":"10.1016\/j.jcf.2021.05.006_bib0004","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.18039.1","article-title":"Recent advances in vasoactive intestinal peptide physiology and pathophysiology: Focus on the gastrointestinal system [version 1; peer review: 4 approved]","volume":"8","author":"Iwasaki","year":"2019","journal-title":"F1000Research"},{"key":"10.1016\/j.jcf.2021.05.006_bib0005","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbapap.2011.03.009","article-title":"Structural difference of Vasoactive Intestinal Peptide in two distinct membrane-mimicking environments","volume":"1814","author":"Umetsu","year":"2011","journal-title":"Biochim Biophys Acta - Proteins Proteomics"},{"key":"10.1016\/j.jcf.2021.05.006_bib0006","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1164\/ajrccm\/143.3_Pt_2.S22","article-title":"VIP as a modulator of lung inflammation and airway constriction","volume":"143","author":"Said","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jcf.2021.05.006_bib0007","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1749-6632.1991.tb37985.x","article-title":"Vasoactive Intestinal Polypeptide (VIP) in Asthma","volume":"629","author":"Said","year":"1991","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jcf.2021.05.006_bib0008","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1196\/annals.1418.014","article-title":"The Vasoactive Intestinal Peptide gene is a key modulator of pulmonary vascular remodeling and inflammation","volume":"1144","author":"Said","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jcf.2021.05.006_bib0009","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1126\/science.4035357","article-title":"Deficient Vasoactive Intestinal Peptide innervation in the sweat glands of cystic fibrosis patients","volume":"229","author":"Heinz-Erian","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.jcf.2021.05.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00293.2013","article-title":"Cystic fibrosis Transmembrane Conductance Regulator dysfunction in VIP knockout mice","volume":"307","author":"Alcolado","year":"2014","journal-title":"Am J Physiol - Cell Physiol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.109.155341","article-title":"Rescue of functional F508del Cystic Fibrosis Transmembrane Conductance Regulator by Vasoactive Intestinal Peptide in the human nasal epithelial cell line JME\/CF15","volume":"331","author":"Rafferty","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jcf.2021.05.006_bib0012","doi-asserted-by":"crossref","DOI":"10.5772\/30840","article-title":"VIP as a corrector of CFTR trafficking and membrane stability.","author":"Chappe","year":"2012","journal-title":"Cyst. Fibros. - Renewed Hopes Through Res."},{"key":"10.1016\/j.jcf.2021.05.006_bib0013","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1152\/ajpcell.00568.2009","article-title":"VIP-dependent increase in F508del-CFTR membrane localization is mediated by PKC\u03b5","volume":"301","author":"Alcolado","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00296.2013","article-title":"VIP regulates CFTR membrane expression and function in Calu-3 cells by increasing its interaction with NHERF1 and P-ERM in a VPAC1- and PKC\u03b5-dependent manner","volume":"307","author":"Alshafie","year":"2014","journal-title":"Am J Physiol - Cell Physiol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0015","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcf.2016.11.002","article-title":"Environmental scan of cystic fibrosis research worldwide","volume":"16","author":"Kelly","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.05.006_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/1179551419851770","article-title":"Cystic Fibrosis\u2013Related Diabetes: pathophysiology and therapeutic challenges","volume":"12","author":"Kelsey","year":"2019","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"10.1016\/j.jcf.2021.05.006_bib0017","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcf.2004.08.001","article-title":"Clinical importance of Cystic Fibrosis-Related Diabetes","volume":"3","author":"Brennan","year":"2004","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.05.006_bib0018","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/path.4634","article-title":"Pancreatic pathophysiology in cystic fibrosis","volume":"238","author":"Gibson-Corley","year":"2016","journal-title":"J Pathol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0019","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1463-1326.2010.01250.x","article-title":"Managing diabetes in cystic fibrosis","volume":"12","author":"Laguna","year":"2010","journal-title":"Diabetes, Obes Metab"},{"key":"10.1016\/j.jcf.2021.05.006_bib0020","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1530\/EJE-14-0644","article-title":"Management of endocrine disease: Cystic Fibrosis-Related Diabetes: Novel pathogenic insights opening new therapeutic avenues","volume":"172","author":"Barrio","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0021","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2337\/dc12-0807","article-title":"Comparison of cystic fibrosis-related diabetes with type 1 diabetes based on a German\/Austrian pediatric diabetes registry","volume":"36","author":"Konrad","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcf.2021.05.006_bib0022","doi-asserted-by":"crossref","unstructured":"Rickels LG and MR. Pancreatogenic (Type 3c) Diabetes. Pancreapedia Exocrine Pancreas Knowl Base 2015. doi:10.3998\/PANC.2015.35.","DOI":"10.3998\/panc.2015.35"},{"key":"10.1016\/j.jcf.2021.05.006_bib0023","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98240","article-title":"Cystic Fibrosis-Related Diabetes is caused by islet loss and inflammation","volume":"3","author":"Hart","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcf.2021.05.006_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic Fibrosis Related Diabetes: Pathophysiology, screening and diagnosis","author":"Granados","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.05.006_bib0025","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.2337\/db13-0510","article-title":"Genetic modifiers of Cystic Fibrosis-Related Diabetes","volume":"62","author":"Blackman","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.jcf.2021.05.006_bib0026","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.2337\/dc10-1279","article-title":"Epidemiology, pathophysiology, and prognostic implications of Cystic Fibrosis-Related Diabetes: A technical review","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcf.2021.05.006_bib0027","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/dmrr.2429","article-title":"Cystic Fibrosis-Related Diabetes compared with type 1 and type 2 diabetes in adults","volume":"29","author":"Konrad","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jcf.2021.05.006_bib0028","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1530\/JME-12-0156","article-title":"Therapeutic potential of VIP vs PACAP in diabetes","volume":"49","author":"Sanlioglu","year":"2012","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0029","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.peptides.2007.04.024","article-title":"Role of VIP and PACAP in islet function","volume":"28","author":"Winzell","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.jcf.2021.05.006_bib0030","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.npep.2006.04.001","article-title":"Vasoactive Intestinal Polypeptide and Pituitary Adenylate Cyclase Activating Polypeptide: Effects on insulin release in isolated mouse islets in relation to metabolic status and age","volume":"40","author":"Persson-Sj\u00f6gren","year":"2006","journal-title":"Neuropeptides"},{"key":"10.1016\/j.jcf.2021.05.006_bib0031","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/diabetes.51.5.1453","article-title":"A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: A potential therapy for type 2 diabetes","volume":"51","author":"Tsutsumi","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.jcf.2021.05.006_bib0032","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2337\/diabetes.49.11.1751","article-title":"Triggering and amplifying pathways of regulation of insulin secretion by glucose","volume":"49","author":"Henquin","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.jcf.2021.05.006_bib0033","article-title":"Disrupted local innervation results in less VIP expression in CF mice tissues","author":"Semaniakou","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.05.006_bib0034","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-4939-1050-2_3","article-title":"Tissue processing and hematoxylin and eosin staining","volume":"1180","author":"Feldman","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF01228307","article-title":"The location of VIP in the pancreas of man and rat","volume":"18","author":"Bishop","year":"1980","journal-title":"Diabetologia"},{"key":"10.1016\/j.jcf.2021.05.006_bib0036","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0167-0115(97)01014-8","article-title":"Evidence that Vasoactive Intestinal Polypeptide is a parasympathetic neurotransmitter in the endocrine pancreas in dogs","volume":"71","author":"Havel","year":"1997","journal-title":"Regul Pept"},{"issue":"1","key":"10.1016\/j.jcf.2021.05.006_bib0037","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1463-1326.2004.00361.x","article-title":"Islet adaptation to insulin resistance: mechanisms and implications for intervention","volume":"7","author":"Ahr\u00e9n","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcf.2021.05.006_bib0038","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00125-009-1314-y","article-title":"Regulation of insulin secretion: A matter of phase control and amplitude modulation","volume":"52","author":"Henquin","year":"2009","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.jcf.2021.05.006_bib0039","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.mayocp.2017.12.003","article-title":"The role of glucagon in the pathophysiology and treatment of type 2 diabetes","volume":"93","author":"H\u00e6dersdal","year":"2018","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.jcf.2021.05.006_bib0040","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3904\/kjim.2016.233","article-title":"Higher glucagon-to-insulin ratio is associated with elevated glycated hemoglobin levels in type 2 diabetes patients","volume":"34","author":"Lee","year":"2019","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jcf.2021.05.006_bib0041","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41598-017-00098-8","article-title":"CFTR is involved in the regulation of glucagon secretion in human and rodent alpha cells","volume":"7","author":"Edlund","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2021.05.006_bib0042","first-page":"131","article-title":"Gene deletion of VIP leads to increased mortality associated with progressive right ventricular hypertrophy","volume":"2","author":"Szema","year":"2014","journal-title":"J Cardiovasc Dis"},{"key":"10.1016\/j.jcf.2021.05.006_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170606","article-title":"NFATc3 and VIP in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease","volume":"12","author":"Szema","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2021.05.006_bib0044","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1210\/en.2002-220354","article-title":"Vasoactive Intestinal Polypeptide\/Pituitary Adenylate Cyclase-Activating Peptide Receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate","volume":"143","author":"Asnicar","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.jcf.2021.05.006_bib0045","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1124\/jpet.108.141143","article-title":"Vasoactive Intestinal Peptide increases Cystic Fibrosis Transmembrane Conductance Regulator levels in the apical membrane of Calu-3 cells through a protein kinase C-dependent mechanism","volume":"327","author":"Chappe","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jcf.2021.05.006_bib0046","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/apha.12427","article-title":"The neuropeptide Vasoactive Intestinal Peptide: Direct effects on immune cells and involvement in inflammatory and autoimmune diseases","volume":"213","author":"Ganea","year":"2015","journal-title":"Acta Physiol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0047","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/icb.2010.29","article-title":"New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes","volume":"88","author":"Jimeno","year":"2010","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0048","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1196\/annals.1317.073","article-title":"VIP and tolerance induction in autoimmunity","volume":"1070","author":"Rosignoli","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jcf.2021.05.006_bib0049","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1002\/1521-4141(200011)30:11<3236::AID-IMMU3236>3.0.CO;2-L","article-title":"Anti-inflammatory properties of the type 1 and type 2 Vasoactive Intestinal Peptide receptors: role in lethal endotoxic shock","volume":"30","author":"Delgado","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0050","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1053\/j.gastro.2006.10.023","article-title":"Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide","volume":"131","author":"Gonzalez-Rey","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcf.2021.05.006_bib0051","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3727\/096368912X657404","article-title":"Mesenchymal stem cells expressing Vasoactive Intestinal Peptide ameliorate symptoms in a model of chronic multiple sclerosis","volume":"22","author":"Cobo","year":"2013","journal-title":"Cell Transplant"},{"key":"10.1016\/j.jcf.2021.05.006_bib0052","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s001250051322","article-title":"Autonomic regulation of islet hormone secretion - Implications for health and disease","volume":"43","author":"Ahr\u00e9n","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.jcf.2021.05.006_bib0053","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0167-0115(84)90066-1","article-title":"Vasoactive Intestinal Polypeptide (VIP) in the pig pancreas: role of VIPergic nerves in control of fluid and bicarbonate secretion","volume":"8","author":"Holst","year":"1984","journal-title":"Regul Pept"},{"key":"10.1016\/j.jcf.2021.05.006_bib0054","series-title":"Regulation of pancreatic secretion","author":"Chandra","year":"2015"},{"key":"10.1016\/j.jcf.2021.05.006_bib0055","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1172\/JCI9387","article-title":"PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance","volume":"105","author":"Jamen","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2021.05.006_bib0056","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/MPA.0b013e318214c783","article-title":"Characterization of intestinal and pancreatic dysfunction in VPAC1-Null mutant mouse","volume":"40","author":"Fabricius","year":"2011","journal-title":"Pancreas"},{"key":"10.1016\/j.jcf.2021.05.006_bib0057","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1749-6632.1996.tb17486.x","article-title":"Enhancement of glucose-induced insulin secretion in transgenic mice overexpressing human VIP gene in pancreatic \u03b2 cells1","volume":"805","author":"Kato","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jcf.2021.05.006_bib0058","doi-asserted-by":"crossref","first-page":"21223","DOI":"10.1016\/S0021-9258(17)31951-8","article-title":"Transgenic mice overexpressing human vasoactive intestinal peptide (VIP) gene in pancreatic \u03b2 cells. Evidence for improved glucose tolerance and enhanced insulin secretion by VIP and PHM-27 in vivo","volume":"269","author":"Kato","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2021.05.006_bib0059","first-page":"456","article-title":"CNS imaging studies in cystic fibrosis patients presenting with sudden neurological events","volume":"6","author":"Wilson","year":"2019","journal-title":"BMJ Open Resp Res"},{"key":"10.1016\/j.jcf.2021.05.006_bib0060","doi-asserted-by":"crossref","unstructured":"Weyler RT, Yurko-Mauro KA, Rubenstein R, Kollen WJW, Reenstra W, Altschuler SM, et\u00a0al. CFTR is functionally active in GnRH-expressing GT1\u20137 hypothalamic neurons. https:\/\/doi.org\/101152\/Ajpcell19992773C563 1999. doi:10.1152\/AJPCELL.1999.277.3.C563.","DOI":"10.1152\/ajpcell.1999.277.3.C563"},{"key":"10.1016\/j.jcf.2021.05.006_bib0061","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1046\/j.1471-4159.1995.64041662.x","article-title":"Cystic Fibrosis Transmembrane Conductance Regulator is found within brain ventricular epithelium and choroid plexus","volume":"64","author":"Hincke","year":"1995","journal-title":"J Neurochem"},{"key":"10.1016\/j.jcf.2021.05.006_bib0062","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/labinvest.2009.28","article-title":"Cystic Fibrosis Transmembrane Conductance Regulator expression in human spinal and sympathetic ganglia","volume":"89","author":"Niu","year":"2009","journal-title":"Lab Investig"},{"key":"10.1016\/j.jcf.2021.05.006_bib0063","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1124\/mol.105.021436","article-title":"Purine release from spinal cord microglia after elevation of calcium by glutamate","volume":"70","author":"Guo","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0064","series-title":"Expression of Cystic Fibrosis Transmembrane Conductance Regulator in ganglia of human gastrointestinal tract","author":"Xue","year":"2016"},{"key":"10.1016\/j.jcf.2021.05.006_bib0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00001756-199801050-00028","article-title":"Cystic Fibrosis Transmembrane Conductance Regulator expression in human hypothalamus","volume":"9","author":"Mulberg","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.jcf.2021.05.006_bib0066","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1002\/jnr.22154","article-title":"Expression and distribution of Cystic Fibrosis Transmembrane Conductance Regulator in neurons of the spinal cord","volume":"87","author":"Guo","year":"2009","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.jcf.2021.05.006_bib0067","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1369\/jhc.2009.953455","article-title":"Expression and distribution of Cystic Fibrosis Transmembrane Conductance Regulator in neurons of the human brain","volume":"57","author":"Guo","year":"2009","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.jcf.2021.05.006_bib0068","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00001756-199701200-00031","article-title":"Cystic fibrosis mRNA expression in rat brain: Cerebral cortex and medial preoptic area","volume":"8","author":"Johannesson","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.jcf.2021.05.006_bib0069","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1172\/JCI118080","article-title":"Expression and localization of the Cystic Fibrosis Transmembrane Conductance Regulator mRNA and its protein in rat brain","volume":"96","author":"Mulberg","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2021.05.006_bib0070","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.chest.2016.11.009","article-title":"Cystic Fibrosis and the Nervous System","volume":"151","author":"Reznikov","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2021.05.006_bib0071","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1152\/physrev.1994.74.4.813","article-title":"Molecular physiology of voltage-gated chloride channels","volume":"74","author":"Pusch","year":"1994","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jcf.2021.05.006_bib0072","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1073\/pnas.1222729110","article-title":"CFTR-deficient pigs display peripheral nervous system defects at birth","volume":"110","author":"Reznikov","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2021.05.006_bib0073","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1242\/dev.113.1.305","article-title":"Expression of the cystic fibrosis gene in human development","volume":"113","author":"Harris","year":"1991","journal-title":"Development"},{"key":"10.1016\/j.jcf.2021.05.006_bib0074","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ppul.20690","article-title":"Evolution of CFTR protein distribution in lung tissue from normal and CF human fetuses","volume":"42","author":"Marcorelles","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0075","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.humpath.2011.04.031","article-title":"Cystic fibrosis Transmembrane Conductance Regulator protein expression in the male excretory duct system during development","volume":"43","author":"Marcorelles","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0076","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/hmg\/2.3.219","article-title":"Cell-specific localization of CFTR mRNA shows developmentally regulated expression in human fetal tissues","volume":"2","author":"Tizzano","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jcf.2021.05.006_bib0077","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1369\/0022155414546190","article-title":"Cystic Fibrosis Transmembrane Conductance Regulator Protein (CFTR) expression in the developing human brain: comparative immunohistochemical study between patients with normal and mutated cftr","volume":"62","author":"Marcorelles","year":"2014","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.jcf.2021.05.006_bib0078","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s00535-019-01610-9","article-title":"Cystic fibrosis Transmembrane Conductance Regulator modulates enteric cholinergic activities and is abnormally expressed in the enteric ganglia of patients with slow transit constipation","volume":"54","author":"Yeh","year":"2019","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0079","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fphys.2017.00835","article-title":"Abnormal CFTR affects glucagon production by islet a cells in cystic fibrosis and polycystic ovarian syndrome","volume":"8","author":"Huang","year":"2017","journal-title":"Front Physiol"},{"key":"10.1016\/j.jcf.2021.05.006_bib0080","series-title":"Glycemic regulation and insulin secretion are abnormal in cystic fibrosis pigs despite sparing of islet cell mass","author":"Uc","year":"2015"},{"key":"10.1016\/j.jcf.2021.05.006_bib0081","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1210\/en.2017-00187","article-title":"CFTR influences beta cell function and insulin secretion through non-cell autonomous exocrine-derived factors","volume":"158","author":"Sun","year":"2017","journal-title":"Endocrinology"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321001338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321001338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:45:26Z","timestamp":1761601526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199321001338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1569199321001338"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2021.05.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VIP reduction in the pancreas of F508del homozygous CF mice and early signs of Cystic Fibrosis Related Diabetes (CFRD)","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2021.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}